IRadimed Corporation
IRMDNASDAQHealthcare● Active
$94.39
+$1.32(+1.42%)
Market Cap$1.2B
P/E Ratio—
52W High$107.9
52W Low$55.109
IRadimed Corporation (IRMD) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
IRMD · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 1, 2026EPS Actual
$0.49
Est. $0.42 · +16.7%
Revenue
$0.02B
Est. $0.02B · +3.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 1, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 2-Quarter EPS Beat Streak
IRMD reports quarterly as a NASDAQ-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 30, 2026 | $0.44 | — | — | — | $0.02B | — |
| ▲ Q2 FY2026 | May 1, 2026 | $0.42 | $0.49 | +16.7% | $0.02B | $0.02B | +3.1% |
| ▲ Q1 FY2026 | Feb 10, 2026 | $0.49 | $0.54 | +10.2% | $0.02B | $0.02B | +5.1% |
| ▼ Q4 FY2025 | Nov 3, 2025 | $0.48 | $0.47 | -2.1% | $0.02B | $0.02B | -1.8% |
| ▲ Q3 FY2025 | Aug 1, 2025 | $0.45 | $0.49 | +8.9% | $0.02B | $0.02B | -0.4% |
| ▼ Q2 FY2025 | May 5, 2025 | $0.43 | $0.42 | -2.3% | $0.02B | $0.02B | +0.9% |
| ▼ Q1 FY2025 | Feb 13, 2025 | $0.45 | $0.44 | -2.2% | $0.02B | $0.02B | +1.0% |
| ▲ Q4 FY2024 | Oct 31, 2024 | $0.39 | $0.43 | +10.3% | $0.02B | $0.02B | -3.2% |
Q3 FY2026
Jul 30, 2026
EPS Actual
—
EPS Est.
$0.44
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 1, 2026Beat
EPS Actual
$0.49
EPS Est.
$0.42
EPS Surpr.
+16.7%
Revenue
$0.02B
Q1 FY2026
Feb 10, 2026Beat
EPS Actual
$0.54
EPS Est.
$0.49
EPS Surpr.
+10.2%
Revenue
$0.02B
Q4 FY2025
Nov 3, 2025Miss
EPS Actual
$0.47
EPS Est.
$0.48
EPS Surpr.
-2.1%
Revenue
$0.02B
Q3 FY2025
Aug 1, 2025Beat
EPS Actual
$0.49
EPS Est.
$0.45
EPS Surpr.
+8.9%
Revenue
$0.02B
Q2 FY2025
May 5, 2025Miss
EPS Actual
$0.42
EPS Est.
$0.43
EPS Surpr.
-2.3%
Revenue
$0.02B
Q1 FY2025
Feb 13, 2025Miss
EPS Actual
$0.44
EPS Est.
$0.45
EPS Surpr.
-2.2%
Revenue
$0.02B
Q4 FY2024
Oct 31, 2024Beat
EPS Actual
$0.43
EPS Est.
$0.39
EPS Surpr.
+10.3%
Revenue
$0.02B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.61 | $0.62 | $0.63 | 1 |
| Q3 FY2027 | $0.58 | $0.59 | $0.60 | 1 |
| Q2 FY2027 | $0.53 | $0.54 | $0.55 | 1 |
| Q1 FY2027 | $0.58 | $0.59 | $0.60 | 1 |
| Q4 FY2026 | $0.60 | $0.60 | $0.61 | 1 |
| Q3 FY2026 | $0.53 | $0.54 | $0.55 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 1, 2026 | +16.7% | $83.44 | $87.15 | +4.45% |
| ▲ Q1 FY2026 | Feb 10, 2026 | +10.2% | $95.97 | $105.15 | +9.57% |
| ▼ Q4 FY2025 | Nov 3, 2025 | -2.1% | $76.81 | $84.11 | +9.50% |
| ▲ Q3 FY2025 | Aug 1, 2025 | +8.9% | $58.34 | $66.17 | +13.42% |
| ▼ Q2 FY2025 | May 5, 2025 | -2.3% | $53.47 | $52.30 | -2.19% |
| ▼ Q1 FY2025 | Feb 13, 2025 | -2.2% | $60.48 | $55.41 | -8.38% |
| ▲ Q4 FY2024 | Oct 31, 2024 | +10.3% | $52.94 | $49.27 | -6.93% |
| ▲ Q3 FY2024 | Aug 1, 2024 | +13.5% | $46.71 | $46.15 | -1.20% |
Q2 FY2026+4.45%
Report Date
May 1, 2026
EPS Beat/Miss
+16.7%
Price Before
$83.44
Price After
$87.15
Q1 FY2026+9.57%
Report Date
Feb 10, 2026
EPS Beat/Miss
+10.2%
Price Before
$95.97
Price After
$105.15
Q4 FY2025+9.50%
Report Date
Nov 3, 2025
EPS Beat/Miss
-2.1%
Price Before
$76.81
Price After
$84.11
Q3 FY2025+13.42%
Report Date
Aug 1, 2025
EPS Beat/Miss
+8.9%
Price Before
$58.34
Price After
$66.17
Q2 FY2025-2.19%
Report Date
May 5, 2025
EPS Beat/Miss
-2.3%
Price Before
$53.47
Price After
$52.30
Q1 FY2025-8.38%
Report Date
Feb 13, 2025
EPS Beat/Miss
-2.2%
Price Before
$60.48
Price After
$55.41
Q4 FY2024-6.93%
Report Date
Oct 31, 2024
EPS Beat/Miss
+10.3%
Price Before
$52.94
Price After
$49.27
Q3 FY2024-1.20%
Report Date
Aug 1, 2024
EPS Beat/Miss
+13.5%
Price Before
$46.71
Price After
$46.15
Avg Beat Reaction+3.86%
Avg Miss Reaction-0.36%
Beat Rate5 / 8 quarters
Largest Move+13.42% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: IRMD ends December
IRadimed Corporation (IRMD) most recently reported earnings on May 1, 2026 for Q2 FY2026, posting EPS of $0.49 — beating the analyst consensus of $0.42 by +16.7%. IRMD has beaten EPS estimates for 2 consecutive quarters. The next IRMD earnings date is expected around September 1, 2026.
Each quarter, investors track IRMD earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. IRMD revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
IRMD's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
IRMD earnings · 5 questionsIRadimed Corporation's next earnings report is expected around September 1, 2026. IRMD typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; IRMD historically reports after market close (AMC).
IRMD earnings datewhen is IRMD earningsIRMD next earnings datewhen does IRMD report earningsIRMD earnings calendar
▸ Source: FMP · IRadimed Corporation SEC filings · US GAAP · IRadimed Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026